Atlas Venture Life Science Advisors LLC Reduces Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Atlas Venture Life Science Advisors LLC trimmed its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 26.7% during the second quarter, Holdings Channel reports. The firm owned 136,979 shares of the company’s stock after selling 50,000 shares during the quarter. Dianthus Therapeutics comprises approximately 0.4% of Atlas Venture Life Science Advisors LLC’s holdings, making the stock its 13th biggest position. Atlas Venture Life Science Advisors LLC’s holdings in Dianthus Therapeutics were worth $3,545,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. WINTON GROUP Ltd purchased a new stake in shares of Dianthus Therapeutics in the 2nd quarter worth about $265,000. American Century Companies Inc. raised its position in Dianthus Therapeutics by 38.6% during the second quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock worth $788,000 after acquiring an additional 8,473 shares during the last quarter. Rhumbline Advisers purchased a new stake in shares of Dianthus Therapeutics in the second quarter valued at about $832,000. Bank of New York Mellon Corp grew its position in shares of Dianthus Therapeutics by 860.5% in the second quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock valued at $2,095,000 after purchasing an additional 72,509 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $112,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on DNTH shares. Robert W. Baird started coverage on Dianthus Therapeutics in a research note on Friday, July 26th. They issued an “outperform” rating and a $58.00 target price on the stock. Cantor Fitzgerald began coverage on Dianthus Therapeutics in a research report on Thursday, June 27th. They issued an “overweight” rating on the stock. Wedbush dropped their price objective on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, August 9th. Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Finally, Lifesci Capital upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $44.71.

Dianthus Therapeutics Price Performance

DNTH opened at $28.96 on Friday. Dianthus Therapeutics, Inc. has a 12 month low of $6.58 and a 12 month high of $33.77. The business has a 50-day moving average of $28.16 and a two-hundred day moving average of $26.09. The stock has a market capitalization of $849.98 million, a price-to-earnings ratio of -4.97 and a beta of 1.85.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The company had revenue of $1.86 million during the quarter, compared to analysts’ expectations of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. Equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.32 earnings per share for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.